Six Month Clinical Outcomes of Sahajanand Medical Technologies Supralimus - Sirolimus Eluting Stent presented at EuroPCR 09

BARCELONA, Spain, May 20, 2009 - Six months Clinical outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success rate (> 97%), and sustained safety.

Presented by Dr. Ricardo A. Costa, of Cardiovascular Research Center, Brazil, Preliminary clinical results at 6 months (60%) from Multicenter E-Series Registry demonstrate clinical effectiveness of Supralimus in preventing revascularization, with only 2% TVR (Target Vessel Revascularization) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patient’s in-Hospital. The stent thrombosis rate (definite/probable, ARC) up to 6 months was less than 1%.

Out-of Hospital adverse events (N=718) included only 2% Cardiac Death, 0.5% MI (Myocardial infarction) and 4.5% of MACE (Major Cardiac Adverse Event). Thus the preliminary data with the Supralimus-Sirolimus Eluting Stent has shown promising results.

The Study was conducted by Dr. Alexandre Abizaid, Dr. Ricardo Costa and others from Jan 2007 which involved 1181 Patients with 1260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years & risk factors included 79% Hypertension, 38% Diabetes, 31% Smoker, 23% with Previous MI, 64% with Dyslipidemia, 34% with Previous PCI and 46% with Family History of CAD. Clinical follow was scheduled at 1, 6, 12 and 24 months. Final analysis of this registry is awaited with great hope & promise.

About Sahajanand Medical Technologies:
Established in the year 1998, SMTPL became the first Indigenous Stent Manufacturer in world to have two DES systems in its product portfolio. SMTPL is the first company to get CE approval for DES with Biodegradable Polymers. All the DES’s are manufactured with proprietary blend of Biodegradable Polymers. The company has both SS & Cobalt Chromium platforms. It is India’s largest manufacturing company for Evidence Based Implantable Medical Devices and Medical Equipments. The products are manufactured conforming to the international quality standards and are offered at the most competitive prices. The company is ISO 9001 and ISO 13485 certified & also obtained CE certification for its advanced range of products. This gives assurance of company’s quality consciousness. For more information log on to: www.smtpl.com.